FDA will survey how visuals distract viewers

Share this article:
The FDA will test broadcast-style ads for a bogus blood pressure drug as part of a survey aimed at determining how visuals may distract viewers from risk information. The survey of 2,400 consumers—ages 40 and up—will feature several executions of the bogus ads to evaluate recall and comprehension of risk information. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.